Gossamer Bio EVP Christian Waage Receives Award of 2.9M Shares

What Happened
Christian Waage, EVP of Technical Operations and Administration at Gossamer Bio (GOSS), received a derivative award on 2026-08-24 covering 2,900,026 shares. The filing lists a per-share price of $0.00 (no cash paid at grant). This is a grant/award (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-08-24; Form 4 filed 2026-08-26 (timely filing).
• Award: 2,900,026 shares (derivative instrument) at $0.00 per share.
• Shares owned after transaction: not specified in the filing.
• Footnote (vesting details): 50% of the total option vests upon FDA approval of seralutinib; the remaining 50% vests at 1/24th per month after approval, subject to continuous service. If FDA approval does not occur within two years, monthly vesting (1/24th of total) begins after that two‑year mark, subject to continuous service.
• Transaction type: A = award/grant of a derivative (option-like) instrument.

Context
This is a contingent equity award tied to a regulatory milestone (FDA approval of seralutinib) and continued service, so no shares are necessarily owned or deliverable today. Such milestone‑based grants are common for biotech executives and do not indicate an immediate cash outlay or a market purchase/sale.